GlassScriptPhysician profile
John P Tauro
NPI 1003915778
$53,730.57
in general payments reported to CMS, 2019-2025
64 companies · $4,565 in 2025
The $4,565 reported for 2025 was more than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
See the full distribution for Neuromuscular Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $15K · 2021: $12K · 2022: $6,687 · 2023: $8,363 · 2024: $6,218 · 2025: $4,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,913 · Travel and Lodging: $52.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,181.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,912.50 |
| Travel and Lodging | $52.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25,100.66 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $16,204.66 | 2019-2022 | |
| Pfizer INC. | $1,626.94 | 2021-2025 | |
| Ucb, INC. | $846.30 | 2023-2025 | Rystiggo, Fintepla, Briviact |
| Teva Pharmaceuticals USA, INC. | $647.08 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lundbeck LLC | $620.93 | 2023-2025 | Vyepti, Rexulti |
| Biogen, INC. | $564.52 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Genzyme Corporation | $488.87 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $475.48 | 2022 | |
| Csl Behring | $435.65 | 2019-2025 | Hizentra |
| Amgen INC. | $407.59 | 2019-2025 | Uplizna, Aimovig |
| Takeda Pharmaceuticals U.S.A., INC. | $389.44 | 2020-2025 | Hyqvia |
| Sk Life Science, INC. | $368.36 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $358.54 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $336.72 | 2019-2025 | Ultomiris |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tauro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.